Normoxemic Extracorporeal Membrane Oxygenation Reduces Infarct Size and Preserves Mitochondrial Integrity in...

Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides cardiopulmonary support during the critical care. Despite its exponential use over last few decades, clinical studies suggest that it does not improve infarct size and mortality in patients suffering from cardiogenic shock after the acute myocardial infarction (AMI). The effect of hyperoxygenated blood under high pressure on the poor outcomes associated with VA-ECMO have not been tested. In this study we tested the hypothesis whether normoxemic oxygenation of blood during provides protection against VA-ECMO associated cardiac damage using a swine model of AMI. Our results indicate that normoxemic VA-ECMO (PaO2 < 200 mmHg), reduces infarct size, activates pro-survival RISK pathway and furthermore preserves mitochondrial structure and function as compared to hyperoxygenated VA-ECMO (PaO2 > 200 mmHg) in ischemia-reperfusion injury. In absence of conclusive clinical trials testing the effect of VA-ECMO blood oxygenation on the patients' outcomes, our findings provide new mechanistic insight into the myocardial effects of VA-ECMO.